SCHEMBL4288469

SCHEMBL4288469

C1CCN(CCNCCN2CCCCC2)CC1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.59
PRMT6 Q96LA8 1/20 0.59
PRMT8 Q9NR22 1/20 0.59
ACE2 Q9BYF1 1/20 0.56
SIGMAR1 Q99720 3/20 0.55
HRH3 Q9Y5N1 1/20 0.52
DPP7 Q9UHL4 1/20 0.52
CA12 O43570 3/20 0.50
CA1 P00915 3/20 0.50
CA2 P00918 3/20 0.50
CA9 Q16790 3/20 0.50
KDM1A O60341 1/20 0.46
NPC1 O15118 1/20 0.42
MAPT P10636 2/20 0.42
ALDH1A1 P00352 1/20 0.42
POLB P06746 1/20 0.42
SCN5A Q14524 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31326654 1.00 CARM1 (0.59) CARM1PRMT6PRMT8ACE2SIGMAR1
SCHEMBL10410535 0.97 CARM1 (0.62) CARM1PRMT6PRMT8ACE2SIGMAR1
SCHEMBL17526217 0.94 CARM1 (0.59) CARM1PRMT6PRMT8ACE2SIGMAR1
SCHEMBL22788741 0.94 CARM1 (0.59) CARM1PRMT6PRMT8ACE2SIGMAR1
SCHEMBL17528553 0.94 CARM1 (0.59) CARM1PRMT6PRMT8ACE2SIGMAR1
SCHEMBL6051858 0.92 ACE2 (0.56) CARM1PRMT6PRMT8ACE2SIGMAR1
SCHEMBL13661585 0.90 HRH3 (0.56) CARM1PRMT6PRMT8ACE2SIGMAR1
SCHEMBL17526226 0.89 ACE2 (0.58) CARM1PRMT6PRMT8ACE2SIGMAR1
SCHEMBL12302972 0.88 CARM1 (0.54) CARM1PRMT6PRMT8ACE2SIGMAR1
SCHEMBL8309995 0.88 CARM1 (0.48) CARM1PRMT6PRMT8ACE2SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3033409-B1 COMPOSITION CATEXEL TECH LIMITED (GB) 2021-09-22 EP disclosed
CN-107709658-B Oxidation process 卡特克塞尔科技有限公司 2021-04-09 CN disclosed
EP-3307940-B1 OXIDATIVE METHOD CATEXEL TECH LIMITED (GB) 2021-03-24 EP disclosed
EP-3307941-B1 OXIDATIVE METHOD CATEXEL TECH LIMITED (GB) 2021-03-24 EP disclosed
US-10882745-B2 Oxidative method CATEXEL TECHNOLOGIES LIMITED (GB) 2021-01-05 US disclosed
US-10815616-B2 Oxidative method CATEXEL TECHNOLOGIES LIMITED (GB) 2020-10-27 US disclosed
CN-107709533-B Oxidation process 卡特克塞尔科技有限公司 2020-09-18 CN disclosed
CN-105452432-B Composition comprising a metal oxide and a metal oxide 切姆森蒂有限公司 2020-04-28 CN disclosed
US-10370621-B2 Bleaching formulations comprising particles and transition metal ion-containing bleaching catalysts CHEMSENTI LIMITED (GB) 2019-08-06 US disclosed
US-20180186634-A1 OXIDATIVE METHOD CATEXEL B.V. (NL) 2018-07-05 US disclosed
US-20180094384-A1 OXIDATIVE METHOD CATEXEL B.V. (NL) 2018-04-05 US disclosed
WO-2016198891-A1 OXIDATIVE METHOD CHEMSENTI LIMITED (GB) 2016-12-15 WO disclosed
WO-2016198890-A1 OXIDATIVE METHOD CHEMSENTI LIMITED (GB) 2016-12-15 WO disclosed
EP-3033409-A1 COMPOSITION Chemsenti Limited (GB) 2016-06-22 EP disclosed
US-20160160160-A1 COMPOSITION CHEMSENTI LIMITED (GB) 2016-06-09 US disclosed
WO-2015022502-A1 COMPOSITION CHEMSENTI LIMITED (GB) 2015-02-19 WO disclosed
WO-2009131246-A1 SORDARIN DERIVATIVES FOR PREVENTING OR TREATING INFECTIOUS DISEASES CAUSED BY PATHOGENIC MICROORGANISMS ASTELLAS PHARMA INC. (JP) 2009-10-29 WO disclosed
WO-2009131246-A1 SORDARIN DERIVATIVES FOR PREVENTING OR TREATING INFECTIOUS DISEASES CAUSED BY PATHOGENIC MICROORGANISMS ASTELLAS PHARMA INC. (JP) 2009-10-29 WO disclosed
US-20060088786-A1 Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus MITSUI CHEMICALS, INC. (JP) 2006-04-27 US disclosed
EP-1484191-A1 REWRITABLE OPTICAL INFORMATION RECORDING MEDIUM AND RECORDING/REPRODUCING METHOD, RECORDING/REPRODUCING DEVICE Sony Corporation (JP) 2004-12-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815616-B2 Oxidative method CAT, LPO, MPO CARM1 1630/4885PRMT6 1322/4885PRMT8 1798/4885
US-20060088786-A1 Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus ALPG, TRPC6, GNRHR CARM1 1297/4885PRMT6 330/4885PRMT8 331/4885
US-10882745-B2 Oxidative method CAT, LPO, GPX4 CARM1 2131/4885PRMT6 2106/4885PRMT8 2559/4885
US-20180094384-A1 OXIDATIVE METHOD CAT, LPO, MPO CARM1 1630/4885PRMT6 1322/4885PRMT8 1798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.